You are about to leave a GSK website

By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.

You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

Educational Opportunities: Join us to learn more about AREXVY. See a list of Educational Opportunities.

For US Healthcare Professionals For US HCPs
Prescribing Information
GSK MedInfo Visit US Patient Site Order AREXVY Visit US Patient Site
USXF HCP Branded with Claims
Tell us what you are looking for in the search box.
Tell us what you are looking for in the search box.
  • Efficacy and Safety
    • Efficacy
    • Secondary Endpoint Results
    • Safety Profile
  • Administration
  • Practice Education
    • Refer AREXVY
    • Coverage for AREXVY
    • Coding and Reimbursement
  • Resources
  • Visit US Patient Site
  • GSK MedInfo
  • Order AREXVY
Indication & Important Safety Info
Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

Important Safety Information

Important Safety Information

  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY​
  • The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
  • Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information.

You are encouraged to report vaccine adverse events to the US Department of Health and Human Services.
Visit www.vaers.hhs.gov to file a report or call 1-800-822-7967.

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891)
Available Monday - Friday
8:30 am - 5:30 pm ET

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891)     Available Monday - Friday     8:30 am - 5:30 pm ET

Description
Educational Event Schedules EHR Resources CDC Supply Information Vaccine Info Statement Medical Inquiries

Legal Notice

Privacy Notice

Interest-based Ads

Contact Us

Unsubscribe

Utility Links
Legal Notice
Privacy Notice
Interest-based Ads
Contact Us
Unsubscribe

Trademarks are owned by or licensed to the GSK group of companies.